Renaissance Technologies LLC Sells 17,465 Shares of VYNE Therapeutics Inc. (NASDAQ:VYNE)

Renaissance Technologies LLC lowered its holdings in VYNE Therapeutics Inc. (NASDAQ:VYNE) by 21.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 63,111 shares of the company’s stock after selling 17,465 shares during the period. Renaissance Technologies LLC owned approximately 0.43% of VYNE Therapeutics worth $124,000 at the end of the most recent quarter.

Separately, Virtu Financial LLC purchased a new position in VYNE Therapeutics in the 1st quarter valued at approximately $50,000. Hedge funds and other institutional investors own 83.78% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.75 price target on shares of VYNE Therapeutics in a report on Thursday, September 12th.

VYNE Therapeutics Stock Up 3.8 %

Shares of VYNE opened at $1.91 on Monday. VYNE Therapeutics Inc. has a twelve month low of $1.57 and a twelve month high of $4.48. The stock has a market cap of $28.17 million, a PE ratio of -0.74 and a beta of 1.40. The business’s 50-day moving average price is $1.84 and its 200-day moving average price is $2.18.

VYNE Therapeutics (NASDAQ:VYNE) last posted its earnings results on Wednesday, August 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The firm had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.11 million. VYNE Therapeutics had a negative return on equity of 43.11% and a negative net margin of 5,849.18%. Analysts expect that VYNE Therapeutics Inc. will post -0.86 earnings per share for the current fiscal year.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.